EP3215186A4 - COMPOSITIONS AND METHODS FOR TREATING HIF-1alpha OVER-EXPRESSING CANCERS - Google Patents

COMPOSITIONS AND METHODS FOR TREATING HIF-1alpha OVER-EXPRESSING CANCERS Download PDF

Info

Publication number
EP3215186A4
EP3215186A4 EP15856516.8A EP15856516A EP3215186A4 EP 3215186 A4 EP3215186 A4 EP 3215186A4 EP 15856516 A EP15856516 A EP 15856516A EP 3215186 A4 EP3215186 A4 EP 3215186A4
Authority
EP
European Patent Office
Prior art keywords
1alpha
compositions
methods
over
expressing cancers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP15856516.8A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3215186A2 (en
Inventor
Wei Li
David Woodley
Mei Chen
Divya SAHU
Hangming DONG
Mengchen ZOU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California USC
Original Assignee
University of Southern California USC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southern California USC filed Critical University of Southern California USC
Publication of EP3215186A2 publication Critical patent/EP3215186A2/en
Publication of EP3215186A4 publication Critical patent/EP3215186A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP15856516.8A 2014-11-04 2015-11-04 COMPOSITIONS AND METHODS FOR TREATING HIF-1alpha OVER-EXPRESSING CANCERS Withdrawn EP3215186A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462075129P 2014-11-04 2014-11-04
PCT/US2015/059104 WO2016073647A2 (en) 2014-11-04 2015-11-04 COMPOSITIONS AND METHODS FOR TREATING HIF-1alpha OVER-EXPRESSING CANCERS

Publications (2)

Publication Number Publication Date
EP3215186A2 EP3215186A2 (en) 2017-09-13
EP3215186A4 true EP3215186A4 (en) 2018-10-24

Family

ID=55910026

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15856516.8A Withdrawn EP3215186A4 (en) 2014-11-04 2015-11-04 COMPOSITIONS AND METHODS FOR TREATING HIF-1alpha OVER-EXPRESSING CANCERS

Country Status (3)

Country Link
EP (1) EP3215186A4 (zh)
CN (1) CN107106669A (zh)
WO (1) WO2016073647A2 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10273294B2 (en) 2010-10-11 2019-04-30 University Of Southern California Compositions and methods for treating HIF-1α over-expressing cancers
CN108337893B (zh) * 2017-12-08 2019-11-26 深圳市人民医院 一种sgRNA及其构建的慢病毒载体和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140199309A1 (en) * 2010-10-11 2014-07-17 University Of Southern California Fragment of secreted heat shock protein-90alpha (hsp90alpha) as vaccines or epitope for monoclonal antibody drugs or target for small molecule drugs against a range of solid human tumors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
CA1292686C (en) 1986-10-27 1991-12-03 Ze'ev Shaked Pharmaceutical compositions of recombinant interleukin-2 and formulation process
CA1294215C (en) 1986-10-27 1992-01-14 Ze'ev Shaked Pharmaceutical compositions of recombinant beta-interferon and formulation processes
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5587384A (en) 1994-02-04 1996-12-24 The Johns Hopkins University Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity
US7342093B2 (en) * 2004-07-23 2008-03-11 University Of Massachusetts Compounds that inhibit Hsp90 protein-protein interactions with IAP proteins
EP2060565A1 (en) * 2007-11-16 2009-05-20 4Sc Ag Novel bifunctional compounds which inhibit protein kinases and histone deacetylases
CN102485720B (zh) * 2009-10-30 2014-08-20 北京科美森医药研发有限公司 热休克蛋白90抑制剂
GB201004761D0 (en) * 2010-03-22 2010-05-05 Medical Res Council Method
JP2015525063A (ja) * 2012-05-16 2015-09-03 シンタ ファーマスーティカルズ コーポレーション 低酸素状態に基づくｈｓｐ９０インヒビターでの治療のための被験者の予備選択

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140199309A1 (en) * 2010-10-11 2014-07-17 University Of Southern California Fragment of secreted heat shock protein-90alpha (hsp90alpha) as vaccines or epitope for monoclonal antibody drugs or target for small molecule drugs against a range of solid human tumors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DIVYA SAHU: "Characterization of a fragment in secreted Hsp90[alpha] with potential therapeutic benefits in wound healing and cancer", 2013, XP055482197, ISBN: 978-1-303-46879-7, Retrieved from the Internet <URL:https://search.proquest.com/docview/1459225249/abstract/67221EC69D7D4FFBPQ/1?accountid=29404> [retrieved on 20180607] *
See also references of WO2016073647A2 *

Also Published As

Publication number Publication date
WO2016073647A2 (en) 2016-05-12
CN107106669A (zh) 2017-08-29
WO2016073647A3 (en) 2016-08-25
EP3215186A2 (en) 2017-09-13

Similar Documents

Publication Publication Date Title
IL263224A (en) Methods and preparations for the treatment of cancer
IL304820A (en) Preparations and methods for the treatment of cancer
EP3166640A4 (en) Combination therapy compositions and methods for treating cancers
EP3377516A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
EP3245225A4 (en) Compositions and methods for treatment and detection of cancers
EP3094352A4 (en) Compositions and methods for treatment and detection of cancers
EP3092254A4 (en) Compounds and compositions for treating her2 positive tumors
EP3200815A4 (en) Methods and compositions for treating cancer
EP3209298A4 (en) Compositions and methods for treating insomnia
EP3373962A4 (en) COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISEASES AND CANCER DISEASES
EP3322439A4 (en) COMPOSITIONS AND METHODS FOR TREATING PERITONEAL CANCERS
EP3189074A4 (en) Compositions and methods for treating and preventing inflammation
EP3177292A4 (en) Compounds and methods for treating cancer
EP3139928A4 (en) Anordrin compositions and methods for treating diseases
EP3189036A4 (en) Compositions and methods for treating proliferation disorders
EP3104880A4 (en) Improved methods for the treatment of vascularizing cancers
IL256523A (en) Compositions and methods for treating cancer
EP3347025A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
EP3215140A4 (en) Compositions and methods of diazeniumdiolate-based prodrugs for treating cancer
EP3154544A4 (en) Compositions and methods for treating cancers
EP3429613A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER
EP3185910A4 (en) Methods and compositions for the treatment of cancer
EP3220908A4 (en) Compositions and methods for treating endometriosis
EP3154952A4 (en) Methods and compositions for treatment of her-positive cancers
IL255638A (en) Compositions and methods for treating cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20170420

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20180926

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/113 20100101ALI20180920BHEP

Ipc: C07K 16/18 20060101ALI20180920BHEP

Ipc: A61K 31/713 20060101ALI20180920BHEP

Ipc: A61K 39/00 20060101AFI20180920BHEP

17Q First examination report despatched

Effective date: 20190801

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20200603